A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PV / polycythemia vera

[Related PubMed/MEDLINE]
Total Number of Papers: 1233
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PV  (>> Co-occurring Abbreviation)
Long Form:   polycythemia vera
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2014 A highly specific q-RT-PCR assay to address the relevance of the JAK2WT and JAK2V617F expression levels and control genes in Ph-negative myeloproliferative neoplasms. ASO, B2M, ET, GUSB, PLTs, PMF
2014 A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. JAK2
2014 Abnormal adhesion of red blood cells in polycythemia vera: a prothrombotic effect? MPN
2014 Analysis of the Ten-Eleven Translocation 2 (TET2) gene mutation in myeloproliferative neoplasms. ET, MPNs, TET2
2014 Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study cohort. ET, MF, MPNs
2014 Application of the optimized CO-rebreathing method for determination of hemoglobin mass in patients with polycythemia vera. BSA, LBM, RCV
2014 Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases. CVT, ET, MPNs, PMF
2014 Chorea disclosing a polycythemia vera. JAK2
2014 Chronic myeloproliferative diseases. ET, PMF
10  2014 Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state. ET, MPN
11  2014 Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. ET
12  2014 Cluster-like headache responsive to phlebotomy. ---
13  2014 Coexistence of myeloproliferative neoplasm and plasma-cell dyscrasia. ET, MGUS, MM, MPNs, PMF
14  2014 Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion gene. EEC, PVSG
15  2014 Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications. ET, IL, JAK2, MPNs
16  2014 Determination of accuracy of polycythemia vera diagnoses and use of the JAK2V617F test in the diagnostic scheme. EMR, MPN
17  2014 Differential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoietic progenitors generated from patient-specific induced pluripotent stem cells. iPSCs
18  2014 Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. DIPSS, ET, MF, MPNs
19  2014 Dkk3 levels in patients with myeloproliferative neoplasms. Dkk-3, ET, MPN, PMF
20  2014 Elevated levels of mast cells are involved in pruritus associated with polycythemia vera in JAK2V617F transgenic mice. ---
21  2014 Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. ET, MF, MPN, PMF
22  2014 Epidemiology of myeloproliferative neoplasms in the United States. ET, MF, MPNs
23  2014 Essential thrombocythemia: Rare cause of chorea. ET, MPD
24  2014 Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm. GP, MPN
25  2014 How common are myeloproliferative neoplasms? A systematic review and meta-analysis. ET, MPNs, PMF
26  2014 Interferon apha 2b for treating patients with JAK2V617F positive polycythemia vera and essential thrombocytosis. ET, IFN
27  2014 Jak-2 positive myeloproliferative neoplasms. CEL-NOS, CML, CNL, ET, MPNs, PMF, TKIs
28  2014 JAK2V617F allele burden in patients with myeloproliferative neoplasms. ARMS-PCR, ET, MF, MPNs, RQ-PCR
29  2014 JAK2V617F allele burden is associated with thrombotic mechanisms activation in polycythemia vera and essential thrombocythemia patients. ET, PLA, TF
30  2014 JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease. ET, UPD
31  2014 JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events. ET, IRR
32  2014 JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan. MPNs, RCM
33  2014 Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs. ET, IFN-gamma, JAK2, STAT1
34  2014 Masked polycythemia vera (mPV): results of an international study. mPV, mPV
35  2014 Masked polycythemia vera diagnosed according to WHO and BCSH classification. BCSH, BM, Hb, Hct, mPV, WHO
36  2014 Molecular genetic tests for JAK2V617F, Exon12_JAK2 and MPLW515K/L are highly informative in the evaluation of patients suspected to have BCR-ABL1-negative myeloproliferative neoplasms. ET, MF, MPN
37  2014 Nitric oxide scavenging by cell-free hemoglobin may be a primary factor determining hypertension in polycythemic patients. ECP, MAP
38  2014 Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation. ET
39  2014 Platelet-related fibrinolysis resistance in patients suffering from PV. Impact of clot retraction and isovolemic erythrocytapheresis. CLT, CR, ECP, MCF
40  2014 Polycythemia vera syndrome--as a protrombothic state. CVD, PC, PS
41  2014 Polycythemia vera transforming to myelofibrosis and then biphenotype acute leukemia. BAL, MF, MPN
42  2014 Rethinking the diagnostic criteria of polycythemia vera. BCSH, BM, mPV, PVSG, WHO
43  2014 Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN). ET, MF, MPN, OS, SEER, US
44  2014 The efficiency of therapeutic erythrocytapheresis compared to phlebotomy: a mathematical tool for predicting response in hereditary hemochromatosis, polycythemia vera, and secondary erythrocytosis. BV, DeltaHct, ER, HH, RBC, SE, TE
45  2014 The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon alpha 2a target JAK2V617F-positive progenitor and stem cells. HSC, MPNs, pegIFNalpha-2a, PMF
46  2014 The role of alpha-acidic glycoprotein in formation of bleeding abnormalities in patients with myeloproliferative neoplasms. AGP, ET, LDH, MPN, PMF
47  2014 The thrombotic events in polycythemia vera patients may be related to increased oxidative stress. MDA, OSI, TOS
48  2014 Vertebral artery thrombosis: a rare presentation of primary polycythaemia. MPN
49  2014 WHO-histological criteria for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes. ET, MPNs, PMF
50  2014 [JAK2V617F Mutation and TNF-alpha Expression in Myeloproliferative Neoplasms and Their Correlation]. ET, MF, MPN
51  2014 [Successful treatment with dasatinib for polycythemia vera patient emerging BCR-ABL positive clone during 13 years of treatment]. Ph, TKI
52  2013 A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. HC, HDACi, MPN, MTD
53  2013 Aberrant expression of signaling proteins in essential thrombocythemia. ERbeta, ET
54  2013 ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera. CAT, ET, TG
55  2013 Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. MPN
56  2013 An unknown cause of aortic valve stenosis: polycythemia vera. Ht
57  2013 Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. FTY720-P, PP2A
58  2013 Are MPNs vascular diseases? ET, MPNs
59  2013 Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms. ET, IFN, MF, MPN
60  2013 Characterization of blood donors with high haemoglobin concentration. Hb
61  2013 Chronic myeloproliferative neoplasms and risk of osteoporotic fractures; a nationwide population-based cohort study. CI, CML, CMPN, ET
62  2013 Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study. ADP, ET, MPN, PRI, VASP, WBC
63  2013 Clinics in diagnostic imaging (146). Polycythaemia vera (PV). ---
64  2013 Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: results of a prospective long-term follow-up. ET, MF, PMF
65  2013 Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study. WBC
66  2013 Elevated nuclear factor erythroid-2 levels promote epo-independent erythroid maturation and recapitulate the hematopoietic stem cell and common myeloid progenitor expansion observed in polycythemia vera patients. CMP, HSC, NF-E2
67  2013 Emerging drugs for polycythemia vera. HU
68  2013 Erythrocytosis in children and adolescents-classification, characterization, and consensus recommendations for the diagnostic approach. ---
69  2013 Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. EPO, RCM, WHO
70  2013 Generation of iPS cells from normal and malignant hematopoietic cells. CML, iPSCs
71  2013 Homoharringtonine is an effective therapy for patients with polycythemia vera or essential thrombocythemia who have failed or were intolerant to hydroxycarbamide or interferon-alpha therapy. ET, HHT
72  2013 Impact of JAK2 V617F mutation on hemogram variation in patients with non-reactive elevated platelet counts. AS-qPCR, CBC, ET, MPDs, MPV, P-LCR, PDW
73  2013 Inheritance of the chronic myeloproliferative neoplasms. A systematic review. AD, CML, ET, MPNs, PMF
74  2013 JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms. ET, JAKs, MPN, PMF
75  2013 JAK2 46/1 haplotype is associated with JAK2 V617F-positive myeloproliferative neoplasms in Japanese patients. CI, ET, JAK2, MPNs, OR, PMF
76  2013 JAK2 mutation-related disease and thrombosis. ET, MPNs
77  2013 JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway. ---
78  2013 Laboratory detection of JAK2V617F in human myeloproliferative neoplasms. ET, PMF
79  2013 Leukocytosis in polycythemia vera and splenomegaly in essential thrombocythemia are independent risk factors for hemorrhage. ET
80  2013 Methylation of SOCS3 in Myeloproliferative Neoplasms and Secondary Erythrocytosis/Thrombocythemia. ET, MPNs, PMF
81  2013 MicroRNA deregulation in polycythemia vera and essential thrombocythemia patients. ET, miRNA
82  2013 MicroRNAs in myeloproliferative neoplasms. ET, miRNA, MPN, PMF
83  2013 Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha-2a. CMR, ET, PEG-IFN-alpha-2a
84  2013 Molecular basis of erythrocyte adhesion to endothelial cells in diseases. PS, RAGE, RBC, RVO
85  2013 Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome. ET, PM
86  2013 Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms. ET, MPN, MPN-SAF, PMF, QOL
87  2013 Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. ET
88  2013 Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. AVWS, CV, ET, MPN
89  2013 Polycythemia vera and the Jak2(V617F) mutation in a case of hereditary spherocytosis. HS
90  2013 Polycythemia vera: current pharmacotherapy and future directions. JAK2
91  2013 Postcoital generalised pruritus as a first symptom of polycythaemia vera. AP, PCP
92  2013 Proteomic analysis reveals heat shock protein 70 has a key role in polycythemia Vera. BFU-E, ET, MPN
93  2013 Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms. JAK, MPNs, mTOR
94  2013 Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. ELN, ET
95  2013 Role of erythrocytes and platelets in the hypercoagulable status in polycythemia vera through phosphatidylserine exposure and microparticle generation. MPs, PCA, PS
96  2013 Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis. ET, JAK, MF
97  2013 Serum hepcidin and growth differentiation factor-15 (GDF-15) levels in polycythemia vera and essential thrombocythemia. CMPD, ET, GDF15
98  2013 Significance of cytogenetic abnormalities in patients with polycythemia vera. ---
99  2013 Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. CI, HR
100  2013 Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy. CTR, MF, Ph-neg-CMNs, SE, TL